Retatrutide is supplied as a research-grade peptide by vendors like Bangkok Peptides for laboratory and preclinical research use only
Primary care providers, who write the bulk of GLP-1 prescriptions, seldom have the resources or time to deliver effective weight management support (source)
It becomes part of their morning ritual, like taking vitamins
#Terrestrial #Semaglutide #MicroarrayPatch #NeedleFree #FirstInHuman #ClinicalTrials #GLP1 #Obesity #Diabetes #DrugDelivery #BiotechNews #Pharmacally Image Credit: Terrenstrial To view or add a comment, sign in *GLP-1 Drugs Are No Longer Just Weight-Loss Medicines*
Some obesity experts have a cautious outlook
The headline results at 80 weeks were: 12 mg dose: average weight loss of 28.3% (approximately 70.3 lbs / 31.9 kg) 9 mg dose: average weight loss of 25.9% (approximately 64.4 lbs / 29.2 kg) 4 mg dose: average weight loss of 19.0% (approximately 47.2 lbs / 21.4 kg) Placebo: average weight loss of just 2.2% Perhaps most striking was the proportion of patients hitting bariatric-surgery-level outcomes: at the highest dose, 45.3% of participants lost 30% or more of their body weight , and 65.3% reduced their BMI to below 30 kg/m meaning they were no longer classified as living with obesity by the end of the trial
